Literature DB >> 28456623

Oral corticosteroid exposure and adverse effects in asthmatic patients.

Patrick W Sullivan1, Vahram H Ghushchyan2, Gary Globe3, Michael Schatz4.   

Abstract

BACKGROUND: Significant adverse effects (AEs) have been associated with continuous exposure to oral corticosteroids (OCSs). The potential association with intermittent exposure is unknown.
OBJECTIVE: We sought to assess the association between OCSs and AEs based on the number of OCS prescriptions.
METHODS: This was a retrospective cohort study of asthmatic patients 18 years and older in the 2000-2014 MarketScan data set. Propensity score matching was used at baseline (12 months before the index date: first OCS use). Logistic regression was used to examine the association between OCSs and new incident AEs (either combined or individual) controlling for covariates. Follow-up continued for 24 months minimum and 10 years maximum after the index date.
RESULTS: There were 72,063 and 156,373 subjects in the OCS and no OCS cohorts, respectively. Subjects taking 4 or more OCS (1-3) prescriptions within the year had 1.29 (1.04) times the odds of experiencing a new AE within the year. Each year of exposure to 4 or more OCS prescriptions (current and past) resulted in 1.20 times the odds of having an AE in the current year. Exposure to 4 or more prescriptions was associated with significantly greater odds of AEs for osteoporosis, hypertension, obesity, type 2 diabetes, gastrointestinal ulcers/bleeds, fractures, and cataracts (odds, 1.21-1.44 depending on the AE).
CONCLUSION: Although previous research has documented the deleterious effect of continuous OCS exposure in patients with severe asthma, our results suggest that each OCS prescription might result in a cumulative burden on current and future health regardless of dose and duration. OCS-sparing strategies are extremely important to improve patient outcomes.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Oral corticosteroids; adverse effects; burst therapy; severe asthma

Mesh:

Substances:

Year:  2017        PMID: 28456623     DOI: 10.1016/j.jaci.2017.04.009

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  58 in total

1.  Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events.

Authors:  P Khoury; K Stokes; M Gadkari; M A Makiya; F Legrand; Z Hu; A Klion; L M Franco
Journal:  Allergy       Date:  2018-07-17       Impact factor: 13.146

2.  How will nanotechnology lead to better control of asthma?

Authors:  Bumhee Yang; Hayoung Choi; Sang-Heon Kim; Ho Joo Yoon; Hyun Lee
Journal:  Ann Transl Med       Date:  2019-10

3.  Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

Authors:  Emeline Brenard; Charles Pilette; Caroline Dahlqvist; Benoît Colinet; Florence Schleich; Florence Roufosse; Antoine Froidure
Journal:  Lung       Date:  2020-02-12       Impact factor: 2.584

4.  Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases.

Authors:  Suidong Ouyang; Caini Liu; Jianxin Xiao; Xing Chen; Andy C Lui; Xiaoxia Li
Journal:  JCI Insight       Date:  2020-02-13

5.  Use of Systemic Corticosteroids for Reasons Other than Asthma in Subjects with Asthma.

Authors:  Keisuke Watanabe; Nobuyuki Horita; Yu Hara; Nobuaki Kobayashi; Takeshi Kaneko
Journal:  Respiration       Date:  2021-09-01       Impact factor: 3.966

6.  Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease.

Authors:  Josefin Eklöf; Truls Sylvan Ingebrigtsen; Rikke Sørensen; Mohamad Isam Saeed; Imane Achir Alispahic; Pradeesh Sivapalan; Jonas Bredtoft Boel; Jette Bangsborg; Christian Ostergaard; Ram Benny Dessau; Ulrich Stab Jensen; Ejvind Frausing Hansen; Therese Sophie Lapperre; Howraman Meteran; Torgny Wilcke; Niels Seersholm; Jens-Ulrik Stæhr Jensen
Journal:  Thorax       Date:  2021-08-26       Impact factor: 9.102

7.  Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR).

Authors:  Ji-Hyang Lee; Hyo-Jung Kim; Chan Sun Park; So Young Park; So-Young Park; Hyun Lee; Sang-Heon Kim; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2022-07       Impact factor: 5.096

8.  Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.

Authors:  Kerry L Hancock; Sinthia Bosnic-Anticevich; John D Blakey; Mark Hew; Li Ping Chung; Biljana Cvetkovski; Scott Claxton; Peter Del Fante; Eve Denton; Joe Doan; Kanchanamala Ranasinghe; Lucy Morgan; Anita Sharma; Peter K Smith; Deb Stewart; Philip J Thompson; Russell Wiseman; John W Upham; Kwok Y Yan; Victoria Carter; Kiranjeet Dhillon; Florian Heraud; Thao Le; Rebecca Vella; David Price
Journal:  Pragmat Obs Res       Date:  2022-07-05

9.  Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration.

Authors:  So Gun Hong; Noriko Sato; Fanny Legrand; Manasi Gadkari; Michelle Makiya; Kindra Stokes; Katherine N Howe; Shiqin Judy Yu; Nathaniel Seth Linde; Randall R Clevenger; Timothy Hunt; Zonghui Hu; Peter L Choyke; Cynthia E Dunbar; Amy D Klion; Luis M Franco
Journal:  Blood       Date:  2020-12-03       Impact factor: 22.113

10.  Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Authors:  Giorgio Walter Canonica; Giorgio Lorenzo Colombo; Paola Rogliani; Pierachille Santus; Claudia Pitotti; Sergio Di Matteo; Chiara Martinotti; Giacomo Matteo Bruno
Journal:  Risk Manag Healthc Policy       Date:  2020-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.